Skip to main content
. 2019 Aug 22;13:889. doi: 10.3389/fnins.2019.00889

FIGURE 4.

FIGURE 4

Detection and quantification of SNCA and pS129 SNCA in human CSF (clinical source) using the Singulex assays. (A) Analysis of SNCA (i) and pS129 SNCA (ii) levels in 5 archival CSF samples of clinical origin (CSF 1–5; ∗PD individuals). (B) Quantification of pS129 SNCA (undetectable) and SNCA levels in the 5 archival clinical CSF samples (CSF 1–5) and in an additional 12 freshly collected clinical CSF samples treated with phosphatase inhibitors (PPIs) at the time of collection (CSF 6–17; ∗PD individuals). (C) (i) Box plot illustrating SNCA levels obtained using the SNCA Singulex assay in the clinical CSF samples, subdivided per group (left: archival CSF samples not treated with PPIs; center: freshly collected, PPIs treated clinical CSF samples; right: all clinical CSF samples). Mean values of SNCA (pg/ml) are in line with previous findings. (ii) Table illustrating statistical distribution of measured values (minimum and maximum, quartiles and mean).